Myriad(US:MYGN)2025-05-06 20:37Financial Performance - Q1 2025 - Total revenue decreased by 3% year-over-year (YOY) [6, 24], but increased by 5% YOY excluding specific factors like UNH GeneSight impact, EndoPredict divestiture, and a one-time retroactive coverage benefit from Q1 2024 [6] - Adjusted Gross Margin increased by 50 basis points YOY [24], reaching 69% in Q1 2025 [24, 40] - Adjusted Operating Expenses increased by 1% YOY [7, 24], with $140.6 million in Q1 2025 compared to $139.1 million in Q1 2024 [42] - Adjusted EPS was $(0.03) in Q1 2025, compared to $(0.01) in Q1 2024 [24, 45] - Adjusted EBITDA was $(0.1) million in Q1 2025, a decrease from $4 million in Q1 2024 [29, 47] - Adjusted free cash flow was $(18.7) million in Q1 2025, compared to $(17.9) million in Q1 2024 [30, 49] Segment Performance - Q1 2025 - Hereditary Cancer testing (HCT) revenue decreased by 2% YOY [11, 12], while HCT affected population revenue and volume grew by 0% and 5% YOY, respectively [12] - MyRisk with RiskScore testing revenue and volume in the affected population grew by 4% and 11% YOY, respectively [12, 15] - Prenatal revenue increased by 11% YOY [10], driven by Foresight and Prequel (+10% volume growth) [6, 18] - GeneSight testing revenue decreased by 20% YOY [12], while testing volume grew by 2% YOY [12] Updated 2025 Financial Guidance - Total revenue guidance lowered to a range of $807 million - $823 million [32], a $35 million reduction at the midpoint [7] - Adjusted operating expenses guidance moderated to a range of $555 million - $565 million [32], a $25 million reduction at the midpoint [7] - Adjusted EPS guidance midpoint is at breakeven, ranging from $(0.02) to $0.02 [7, 32]